Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children

This single-arm, multicenter clinical study will treat the patient who have relapsed or refractory neuroblastoma with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor(CAR)that will bind to tumour cells modified to express the GD2 protein on the cell surface. The study will determine if these modified T cells help the body's immune system eliminate tumour cells .The trial will also study the safety of treatment for CAR-T, how long CAR-T cells stay in the patient's body and the impact on this treatment for survival.

Study Overview

• Status: Unknown
• Conditions: Relapsed or Refractory Neuroblastoma
• Intervention / Treatment: Biological: GD2-targeted CAR-T cells

Detailed Description

This is a single-arm, multicenter clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of relapsed or refractory neuroblastoma in children. The study will be conducted using a phaseⅠ/Ⅱdesign the study will have the following sequential phases: part A (screening, leukapheresis,cell product preparation and cytoreductive chemotherapy) and part B (treatment and follow-up). the follow-up period for each participant is approximately 35 months after the final CAR-T infusion. The total duration of the study are expected to be approximately 3 years. A total of 22 patients may be enrolled over a period of 3 years.

• Study Type: Interventional
• Enrollment (Anticipated): 22
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210008
      • Recruiting
      • Nanjing Children's Hospital
      • Contact: Yongjun Fang, Ph.D; Phone Number: 18951769586; Email: fyj322@189.cn
      • Principal Investigator: Yongjun Fang, Ph.D
  • Shanghai
    • Shanghai, Shanghai, China, 201102
      • Recruiting
      • Children's Hospital of Fudan University
      • Contact: Kuiran Dong, Ph.D; Phone Number: 18017591156; Email: kuirand@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 14 years (CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Up to diagnostic criteria for relapsed or refractory neuroblastoma or high-risk patients，including:

   • Relapsed neuroblastoma : Children diagnosed with neuroblastoma who after standard treatment and remission, present lesions again and cannot reach complete remission with surgery.
   • Refractory neuroblastoma : ① Untreated patients that do not have to reach completes remission after 4 courses of chemotherapy in accordance with standard regimens nor reach complete remission with surgery. ② High-risk patients : Who have cell genetic variation, such as MYCN amplification or bone marrow metastasis.
2. Relapsed or Refractory Neuroblastoma: Target, of which expression may be intervened , discovered with Immunohistochemistry can be selected (GD2 +) (more than 50% of tumor cells is at least 2+ , adopting anti-GD2-mAb14G2a ).
3. Age: 1~14 years old of age at the time of enrollment, male or female.
4. Physical condition is good: ECOG score reaches 0 to 2 points.
5. Body weights greater than or equal to 10 kg.
6. White blood cell counts acuity≥ 1.0 x10^9 / L.
7. Estimated survival times > 90 days.
8. Voluntary participation, good compliance, can cooperate with the experimental observation and signed an informed consent form.

Exclusion Criteria:

1. Positive pregnancy tests.
2. Uncontrolled infection.
3. HIV infection, hepatitis B or C activity period.
4. Patients who need long-term immunosuppressive therapy (Such as allergies, autoimmune diseases, GVHD, etc.)
5. Combined activity of the central nervous system malignant tumor invasion.
6. Abnormal coagulation function, patients with severe thrombosis.

7. Organ failure

   1. Heart：class Ⅱ or above.
   2. Liver：class Ⅱ or above( Refer to Classification of Wuhan Conference (1983)).
   3. Kidney: The second stage of renal insufficiency or above.
   4. Lung: class Ⅱdecreased slightly or above.
   5. Brain: The central nervous system transfer or have active lesions.
8. Patients who have participated in other clinical trials or other clinical trials in the past 30 days.
9. The researchers believe that the patient is not suitable to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: single arm; Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form：injection Dosage:100ml/time Frequency:0 days,the first day,the second day,29 days,30 days Duration:Total five times	Biological: GD2-targeted CAR-T cells; This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy	The overall efficiency will be determined by the evaluation of CT/MRI scans and bone marrow biopsy. Assessment of tumor remission rate according to International Neuroblastoma Response Criteria. The overall efficiency = (complete remission (CR) number + the number of very good partial remission (VGPR) number + partial response (PR) number + mixed reaction (MR) number + no response (NR) number) / total number of cases receiving treatment.	28d,56d,90d

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression free survival	From the test of the progression of disease progression or the interval between disease and death.	3 years
Overall survival	For all patients, overall survival refers to the period from being included in the test group to death caused by any reason	3 years
Patients-based Quality of Life Evaluation	According to EORTC quality of life measurement scale PedsQL4.0_ children's quality of life of the core scale of the evaluation and comparison of physical condition before and after treatment.	3 years
3°or above incidence rate of serious adverse reaction related to treatment	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	3 years

Collaborators and Investigators

• Sponsor: Sinobioway Cell Therapy Co., Ltd.
• Collaborators: Children's Hospital of Fudan University; Nanjing Children's Hospital
• Investigators: Principal Investigator: Yongjun Fang, Ph.D, Nanjing Children's Hospital; Principal Investigator: Kuiran Dong, Ph.D, Children's Hospital of Fudan University

Publications and helpful links

General Publications

• Thomas S, Straathof K, Himoudi N, Anderson J, Pule M. An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers. PLoS One. 2016 Mar 31;11(3):e0152196. doi: 10.1371/journal.pone.0152196. eCollection 2016.

Helpful Links

• An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers

Study record dates

Study Major Dates

• Study Start: September 1, 2016
• Primary Completion (ANTICIPATED): September 1, 2020
• Study Completion (ANTICIPATED): September 1, 2020

Study Registration Dates

• First Submitted: September 26, 2016
• First Submitted That Met QC Criteria: September 27, 2016
• First Posted (ESTIMATE): September 29, 2016

Study Record Updates

• Last Update Posted (ACTUAL): March 14, 2017
• Last Update Submitted That Met QC Criteria: March 13, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Keywords: CAR-T; neuroblastoma
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroectodermal Tumors, Primitive; Neuroectodermal Tumors, Primitive, Peripheral; Neuroblastoma
• Other Study ID Numbers: WM-CART-07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO